Aducanumab (Aduhelm): Alzheimer's Drug Overview, Efficacy & Controversy
Aducanumab (brand name Aduhelm) received accelerated FDA approval in 2021 for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. It represents the first disease-modifying therapy targeting amyloid-beta plaques.
Mechanism of Action
A monoclonal antibody that binds aggregated amyloid-beta, promoting plaque clearance and potentially slowing neurodegeneration.
Clinical Trial Evidence
- EMERGE trial: Showed statistically significant reduction in clinical decline at high dose.
- ENGAGE trial: Did not meet primary endpoint; results were discordant with EMERGE.
The FDA based approval on EMERGE and a post-hoc analysis of combined data—a decision that sparked significant debate.
Dosing & Administration
Intravenous infusion every 4 weeks. Starting dose 10 mg/kg, titrated to 20 mg/kg over several months if tolerated.
Common Side Effects
- Amyloid-related imaging abnormalities (ARIA): brain edema (ARIA-E) or microhemorrhages (ARIA-H)
- Headache, dizziness, fatigue, confusion, nausea, falls
Controversies & Considerations
- Mixed efficacy data; clinical significance of cognitive benefit debated.
- High cost and need for regular MRI monitoring for ARIA.
- Ongoing Phase 4 trials required to confirm long-term benefit.
Patients and clinicians should weigh potential modest benefits against risks, monitoring burden, and cost through shared decision-making.
Prescription Medications - Related Articles
- Understanding and Treating Isolated Systolic Hypertension
- Ritalin (Methylphenidate): Uses, Benefits & Side Effects
- Percocet and Pancreatitis: Understanding Pain Relief Options
- The Seven Rights of Medication Administration: Preventing Errors
- Affordable Prescription Drugs Online: A Simple Buying Guide
- Blood Pressure Medication & Organ Health: Risks & Monitoring
- Managing Cellcept-Induced Diarrhea: Tips & Prevention
